Head and Neck Squamous Cell Carcinoma Epidemiology Forecast to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Head and Neck Squamous Cell Carcinoma – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

In the 8MM, the diagnosed incident cases of HNC are expected to increase from 279,734 cases in 2020 to 338,790 cases in 2030, at an Annual Growth Rate (AGR) of 2.11%. In 2030, urban China will have the highest number of diagnosed incident cases of HNC in the 8MM, with 141,960 diagnosed incident cases, whereas Italy will have the fewest diagnosed incident cases with 13,720 cases.

In the 8MM, the five-year diagnosed prevalent cases of HNC are expected to increase from 836,755 cases in 2020 to 1,018,417 cases in 2030, at an AGR of 2.17%. The publisher epidemiologists attribute the increase in the five-year diagnosed prevalent cases and diagnosed incident cases of HNC to diagnosed incidence rate, regression trend analysis and survival rates, and population dynamics in each market.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report provides a 10-year epidemiological forecast of the diagnosed incident cases of HNCs.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global HNCs market.
• Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HNCs therapeutics in each of the markets covered.
• Understand magnitude of HNCs by stage at diagnosis, risk factors, EGFR mutation, PD-L1 expression by CPS scores, and surgical and radiotherapy vs. systemic treatment.

Key Topics Covered:

1 Head and Neck Squamous Cell Carcinoma: Executive Summary

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC

2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC by Histology Distribution

2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of HNC by Clinical Stage at Diagnosis for Squamous Cell Carcinoma

2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)

2.4.7 Forecast Assumptions and Methods: Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)

2.4.8 Forecast Assumptions and Methods: Tobacco Smoking History

2.4.9 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of HNC

2.5 Epidemiological Forecast for HNC (2020-2030)

2.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])

2.5.2 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-]) by Risk Factor, Histology Distribution, and Stage at Diagnosis

2.5.3 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer (ICD-10 = C00-C06, C09, C12-C14, C32, and C10 [HPV-])

2.5.4 Diagnosed Incident Cases of Oropharynx Cancer (ICD-10 = C10)

2.5.5 Diagnosed Incident Cases of Oropharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis

2.5.6 Diagnosed Incident Cases of Nasopharynx Cancer (ICD-10 = C11)

2.5.7 Age-Specific Diagnosed Incident Cases of Nasopharynx Cancer

2.5.8 Sex-Specific Diagnosed Incident Cases of Nasopharynx Cancer

2.5.9 Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis

2.5.10 Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer

2.5.11 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (ICD-10 = C07-C08 and C30-C31)

2.5.12 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

2.5.13 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

2.5.14 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Risk Factors, Histology Distribution, and Stage at Diagnosis

2.5.15 Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/lhq58h

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900